Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and essential metabolic functions for the host and the microbiome.
See more about our approach
Pharmabiome has developed unique technologies to access these functional groups of bacteria and then design and produce functional consortia at scale. Read about our differentiated technologies
We are a pre-clinical stage spinoff from the ETH Zurich, combining key expertise in the microbiome, biotechnology and the molecular disease mechanisms that involve the microbiome.
See the expertise of our board, advisors and operational team
We unlock the therapeutic potential of the microbiome through our deep understanding of microbial function, host-microbiome interactions and disease-specific dynamics, enabling us to discover and develop therapeutics and bring the hope for cure to patients.
We strive to become the leading global experts in the development of bacterial consortia based on mixed cultures. Our mission is to unlock the therapeutic potential of the microbiome through a deep understanding of its function and the disease-specific dynamics.
Research informs our belief that the smallest relevant biological unit is function, delivered by a network of intestinal bacteria. Bacteria need to interact in a functional network and achieve a balance so that the microbiome can work.more about function
The human microbiome fulfills a variety of functions. Each function is encoded in a set of bacteria that each have several functions under different circumstances. A bacterial consortium needs to be versatile, balanced and cover all the essential functions.more about science
We take a bottom-up approach and engineer bacterial consortia based on their interactions. Our deep under-standing of function drives the selection of individual strains and our technology to co-culture them is groundbreaking.more about our approach
Microbiome therapies go beyond FMT and are targeted to introduce a functionality. Starting with the biology of a specific disease, a tailored consortium of bacteria is mixed and co-cultured to reverse a dysbiosis.more about therapies
For IBD Day 2019 we have supported a video artist who sheds light on the unmet medical need. Addressing the microbiome may open the door to a curative therapy.read more
PharmaBiome was awarded with the seal of excellence from the European Commission Horizon2020 programm …read more
PharmaBiome founder and leader Tomas de Wouters recognized …read more
Philip Hemme from Labiotech interviews Dr. Tomas de Wouters about our unique approach to functioning bacterial mixes …read more
We are happy to be included in the list of the top 100 startups in Switzerland. The third time is a charm …read more
PharmaBiome wins the ETH Spark Award 2018. We are proud to be ETH’s most promising invention filed for patent in 2017.read more
PharmaBiome receives the SME Instrument Phase I grant from the European Commission’s Horizon2020 programme. The highly competitive programme …read more
The public was invited to vote for the venture-supported startups of the last 12 years and nominate the companies that have the potential to change the world.read more
PharmaBiome is again listed among the Top100 Startups in Switzerland.read more
PharmaBiome enters the Top100 Startups Switzerland ranking. Tomas de Wouters introduces PharmaBiome to investors and entrepreneurs.read more